This is a summary of the European public assessment report (EPAR) for Tobi Podhaler. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tobi Podhaler.
- What is Tobi Podhaler?
Tobi Podhaler is a medicine that contains the active substance tobramycin. It is available as capsules (28 mg) containing a dry powder for inhalation using a portable inhaler device.
- What is Tobi Podhaler used for?
Tobi Podhaler is used to suppress chronic lung infection caused by bacteria called Pseudomonas aeruginosa in adults and children aged six years and over who have cystic fibrosis. Cystic fibrosis is an inherited disease that affects the cells in the lungs and the glands in the gut and pancreas which secrete fluids such as mucus and digestive juices. The accumulation of mucus in the lungs allows bacteria to grow more easily causing infections, lung damage and breathing problems. Bacterial lung infection with P. aeruginosa is frequent in cystic fibrosis patients.
Because the number of patients with cystic fibrosis and P. aeruginosa bacterial lung infection is low, the disease is considered ‘rare’ and Tobi Podhaler was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 March 2003.
The medicine can only be obtained with a prescription.
- How is Tobi Podhaler used?
Tobi Podhaler is inhaled using a hand-held device called Podhaler. The capsules are only to be inserted into the Podhaler and must never be swallowed. The recommended dose is four capsules twice a day (as close as possible to 12 hour intervals) for four weeks, followed by four weeks without treatment. The patient should continue with a cycle of four weeks ‘on’ treatment followed by four weeks ‘off’ treatment for as long as the doctor believes the patient is benefiting from it. If the patient’s lung infection gets worse, the doctor should consider replacing or adding another treatment to Tobi Podhaler. For more information on how to use Tobi Podhaler, see the instructions in the package leaflet.
- How does Tobi Podhaler work?
The active substance in Tobi Podhaler, tobramycin, is an antibiotic that belongs to the group ‘aminoglycosides’. It works by disrupting the production of proteins that P. aeruginosa needs to build its cell walls. This damages the bacteria and eventually kills them.
Tobramycin is a well-known antibiotic that has been used to treat lung infection in cystic fibrosis patients, available in the form of a solution used with a nebuliser (a machine that changes a solution into an aerosol that the patient can breathe in). Tobi Podhaler is intended to increase the convenience of taking tobramycin for patients.
- How has Tobi Podhaler been studied?
The applicant presented data on experimental models with Tobi Podhaler and an existing nebuliser solution containing tobramycin called Tobi. They also presented data from the published literature.
Tobi Podhaler was studied in two main trials in patients who had cystic fibrosis with P. aeruginosa lung infection. The first trial, which involved 102 patients aged six to 21 years, compared Tobi Podhaler with placebo (a dummy treatment), while the second, involving 553 mostly adult patients, compared it with Tobi. The trials lasted 24 weeks (three treatment cycles). The main measure of effectiveness was the change in FEV1 at the end of the treatment period of cycle 1 in the first study and at the end of the treatment period of cycle 3 in the second study. FEV1 is the most air a person can breathe out in one second.
- What benefit has Tobi Podhaler shown during the studies?
Tobi Podhaler was more effective than placebo in treating P. aeruginosa infection in patients with cystic fibrosis. After four weeks of treatment, the patients taking Tobi Podhaler had an improvement in FEV1 of 13.2%, while patients taking placebo had a reduction in FEV1 of around 0.6%. When the patients in the placebo group were switched to Tobi Podhaler for the second and third cycles they also experienced a similar improvement in FEV1. The effect of Tobi Podhaler was similar to that of Tobi after three cycles of treatment.
- What is the risk associated with Tobi Podhaler?
The most common side effects with Tobi Podhaler (seen in more than 1 patient in 10) are haemoptysis (coughing up blood), dyspnoea (difficulty breathing), dysphonia (hoarseness), cough and productive cough (producing mucus), oropharyngeal pain (affecting the mouth and throat) and pyrexia (fever). For the full list of all side effects reported with Tobi Podhaler, see the package leaflet.
Tobi Podhaler should not be used in people who may be hypersensitive (allergic) to tobramycin, any aminoglycoside or any of the other ingredients.
- Why has Tobi Podhaler been approved?
The CHMP decided that Tobi Podhaler’s benefits are greater than its risks, since it is effective at treating lung infection in cystic fibrosis patients and given its added convenience for patients, and recommended that it be given marketing authorisation.
- Other information about Tobi Podhaler
The European Commission granted a marketing authorisation valid throughout the European Union for Tobi Podhaler to Novartis Europharm Limited on 20 July 2011. The marketing authorisation is valid for five years, after which it can be renewed.
For more information about treatment with Tobi Podhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This EPAR was last updated on 21/12/2015 .
29/10/2015 Tobi Podhaler -EMEA/H/C/002155 -II/0030
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antibacterials For systemic use
Tobi Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. See sections 4.4 and 5.1 regarding data in different age groups.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Changes since initial authorisation of medicine
|Name||Language||First published||Last updated|
|Tobi Podhaler : EPAR - Procedural steps taken and scientific information after authorisation||SV = svenska||03/05/2012||21/12/2015|
|Tobi Podhaler-H-C-2155-P46-026: EPAR - Assessment Report||SV = svenska||17/12/2015|
|Tobi Podhaler-H-C-2155-P46-0024 : EPAR - Assessment Report||SV = svenska||15/10/2015|
|Tobi Podhaler-H-C-2155-II-0027-G : EPAR - Assessment Report - Variation||SV = svenska||23/01/2015|
|Tobi Podhaler : EPAR - Paediatric investigation plan compliance statement||SV = svenska||23/01/2015|
|Tobi Podhaler-H-C-2155-PSUV-0015 : EPAR - Scientific conclusion and grounds recommending the variation to the terms of the marketing authorisation||SV = svenska||16/12/2013|
Initial marketing-authorisation documents
|Name||Language||First published||Last updated|
|Tobi Podhaler : EPAR - Public assessment report||SV = svenska||25/08/2011|
|CHMP summary of positive opinion for Tobi Podhaler||SV = svenska||24/09/2010|
This medicine is approved for use in the European Union